

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 10/29/1946
Sex: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

Motor and Sensory Neuropathy Evaluation with Reflex to Titer and Neuronal Immunoblot

ARUP test code 2007966

MAG Antibody, IgM Elisa <1000 TU (Ref Interval: 0-999)
INTERPRETIVE INFORMATION: MAG Antibody, IgM ELISA
An elevated IgM antibody concentration greater than 999 TU against myelin-associated glycoprotein (MAG) suggests active demyelination in peripheral neuropathy. A normal concentration (less than 999 TU) generally rules out an anti-MAG antibody-associated peripheral neuropathy.
TU=Titer Units
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

SGPG Antibody, IgM 0.07 IV (Ref Interval: 0.00-0.99)
INTERPRETIVE INFORMATION: SGPG Antibody, IgM
The majority of sulfate-3-glucuronyl paragloboside (SGPG) IgM-positive sera will show reactivity against MAG. Patients who are SGPG IgM positive and MAG IgM negative may have multi-focal motor neuropathy with conduction block.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Purkinje Cell/Neuronal Nuclear IgG Scrn None Detected (Ref Interval: None Detected)
ANNA-1, ANNA-2, PCCA-1 or PCCA-Tr(DNER) antibodies not detected. No further testing will be performed.
INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-105-132240
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 3 | Printed: 9/29/2022 2:17:59 PM

Asialo-GM1 Antibodies, IgG/IgM	8 IV	(Ref Interval: 0-50)
GM1 Antibodies, IgG/IgM	12 IV	(Ref Interval: 0-50)
GD1a Antibodies, IgG/IgM	7 IV	(Ref Interval: 0-50)
GD1b Antibodies, IgG/IgM	13 IV	(Ref Interval: 0-50)
GQ1b Antibodies, IgG/IgM	10 IV	(Ref Interval: 0-50)

INTERPRETIVE INFORMATION: Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies, IgG/IgM

29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive

Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1), and the neutral glycolipid, asialo GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80 percent of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
MAG Antibody, IgM Elisa	22-105-132240	4/15/2022 11:30:00 AM	4/18/2022 9:59:05 PM	4/20/2022 10:13:00 PM
SGPG Antibody, IgM	22-105-132240	4/15/2022 11:30:00 AM	4/18/2022 9:59:05 PM	4/20/2022 10:13:00 PM
Purkinje Cell/Neuronal Nuclear IgG Scrn	22-105-132240	4/15/2022 11:30:00 AM	4/18/2022 9:59:05 PM	4/20/2022 2:12:00 PM
Asialo-GM1 Antibodies, IgG/IgM	22-105-132240	4/15/2022 11:30:00 AM	4/18/2022 9:59:05 PM	4/21/2022 4:02:00 AM
GM1 Antibodies, IgG/IgM	22-105-132240	4/15/2022 11:30:00 AM	4/18/2022 9:59:05 PM	4/21/2022 4:02:00 AM
GD1a Antibodies, IgG/IgM	22-105-132240	4/15/2022 11:30:00 AM	4/18/2022 9:59:05 PM	4/21/2022 4:02:00 AM
GD1b Antibodies, IgG/IgM	22-105-132240	4/15/2022 11:30:00 AM	4/18/2022 9:59:05 PM	4/21/2022 4:02:00 AM
GQ1b Antibodies, IgG/IgM	22-105-132240	4/15/2022 11:30:00 AM	4/18/2022 9:59:05 PM	4/21/2022 4:02:00 AM

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-105-132240
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 9/29/2022 2:17:59 PM